Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018-2022.

The global incidence of invasive pneumococcal disease (IPD) decreased after the switch from PCV7 to PCV13 in 2010. However, serotype 3 remains the leading cause of IPD in Catalonia (Spain), due to the low effectiveness of PCV13 against it. This study aimed to analyze the clinical, epidemiological, a...

ver descrição completa

Detalhes bibliográficos
Autores: Fernandez de Sevilla M, Alcaraz-Soler C, Soldevila N, Izquierdo C, Esteva C, Moraga-Llop F, González-Peris S, Ciruela P, Díaz-Conradi A, Pérez-Argüello A, Viñado B, Domínguez A, García-García JJ, Muñoz-Almagro C
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2025
País:España
Recursos:Fundació Sant Joan de Déu
Repositório:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p28559
Acesso em linha:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=28559
Access Level:Acceso aberto
Palavra-chave:Invasive pneumococcal disease
PCV13
PCV15
PCV20
Pneumococcal conjugate vaccine
Pneumonia
Serotype
Serotype 3
Vaccine failure
id ES_e4d708e51bee283df83c36e0fee1503d
oai_identifier_str oai:fsjd.fundanetsuite.com:p28559
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018-2022.Fernandez de Sevilla MAlcaraz-Soler CSoldevila NIzquierdo CEsteva CMoraga-Llop FGonzález-Peris SCiruela PDíaz-Conradi APérez-Argüello AViñado BDomínguez AGarcía-García JJMuñoz-Almagro CInvasive pneumococcal diseasePCV13PCV15PCV20Pneumococcal conjugate vaccinePneumoniaSerotypeSerotype 3Vaccine failureThe global incidence of invasive pneumococcal disease (IPD) decreased after the switch from PCV7 to PCV13 in 2010. However, serotype 3 remains the leading cause of IPD in Catalonia (Spain), due to the low effectiveness of PCV13 against it. This study aimed to analyze the clinical, epidemiological, and microbiological characteristics of IPD in children over 5 years and evaluate the potential impact of new vaccines (PCV15 and PCV20). A 5-year prospective observational study was conducted from 2018 to 2022, including children up to 18 hospitalized with IPD at three major children's hospitals in Catalonia. Data on clinical, epidemiological, and microbiological factors were collected. A total of 220 episodes were identified, with a median age of 33.0 months (range 0-209). Comparing pre-pandemic (2018-2019) to early pandemic years (2020-2021), the IPD rate in children < 18 years decreased by 60.6% (p < 0.001). However, no significant change was observed when comparing 2022 to 2018. The most common diagnoses were pneumonia (61.8%), meningitis (14.5%), and bacteremia without focus (13.2%). Serotype 3 was the leading cause (35.1%) of IPD and was associated with complicated pneumonia (84.7%) and vaccine failure (73.6%). Ninety-three IPD episodes (45.4%) were caused by PCV13 serotypes, 97 (47.3%) by PCV15 serotypes, and 132 (64.4%) by PCV20 serotypes. CONCLUSION: The incidence of IPD has remained stable, except for a decrease during the pandemic. Serotype 3 was the most common, often associated with vaccine failures and severe pneumonia. PCV15 and PCV20 vaccines could offer better coverage against circulating serotypes and further reduce IPD incidence in Catalonia. WHAT IS KNOWN: • Serotype 3 remains a leading cause of invasive pneumococcal disease (IPD) despite inclusion in PCV13 due to its limited vaccine effectiveness. • IPD incidence decreased globally during the COVID-19 pandemic, likely due to public health measures. WHAT IS NEW: • In Catalonia, serotype 3 continues to dominate pediatric IPD cases and is frequently associated with complicated pneumonia and vaccine failure. • PCV15 and PCV20 offer broader serotype coverage and may significantly improve IPD prevention in children.SPRINGER2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=28559EUROPEAN JOURNAL OF PEDIATRICSISSN: 03406199ISSNe: 14321076reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p285592026-05-27T12:37:41Z
dc.title.none.fl_str_mv Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018-2022.
title Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018-2022.
spellingShingle Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018-2022.
Fernandez de Sevilla M
Invasive pneumococcal disease
PCV13
PCV15
PCV20
Pneumococcal conjugate vaccine
Pneumonia
Serotype
Serotype 3
Vaccine failure
title_short Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018-2022.
title_full Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018-2022.
title_fullStr Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018-2022.
title_full_unstemmed Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018-2022.
title_sort Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018-2022.
dc.creator.none.fl_str_mv Fernandez de Sevilla M
Alcaraz-Soler C
Soldevila N
Izquierdo C
Esteva C
Moraga-Llop F
González-Peris S
Ciruela P
Díaz-Conradi A
Pérez-Argüello A
Viñado B
Domínguez A
García-García JJ
Muñoz-Almagro C
author Fernandez de Sevilla M
author_facet Fernandez de Sevilla M
Alcaraz-Soler C
Soldevila N
Izquierdo C
Esteva C
Moraga-Llop F
González-Peris S
Ciruela P
Díaz-Conradi A
Pérez-Argüello A
Viñado B
Domínguez A
García-García JJ
Muñoz-Almagro C
author_role author
author2 Alcaraz-Soler C
Soldevila N
Izquierdo C
Esteva C
Moraga-Llop F
González-Peris S
Ciruela P
Díaz-Conradi A
Pérez-Argüello A
Viñado B
Domínguez A
García-García JJ
Muñoz-Almagro C
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Invasive pneumococcal disease
PCV13
PCV15
PCV20
Pneumococcal conjugate vaccine
Pneumonia
Serotype
Serotype 3
Vaccine failure
topic Invasive pneumococcal disease
PCV13
PCV15
PCV20
Pneumococcal conjugate vaccine
Pneumonia
Serotype
Serotype 3
Vaccine failure
description The global incidence of invasive pneumococcal disease (IPD) decreased after the switch from PCV7 to PCV13 in 2010. However, serotype 3 remains the leading cause of IPD in Catalonia (Spain), due to the low effectiveness of PCV13 against it. This study aimed to analyze the clinical, epidemiological, and microbiological characteristics of IPD in children over 5 years and evaluate the potential impact of new vaccines (PCV15 and PCV20). A 5-year prospective observational study was conducted from 2018 to 2022, including children up to 18 hospitalized with IPD at three major children's hospitals in Catalonia. Data on clinical, epidemiological, and microbiological factors were collected. A total of 220 episodes were identified, with a median age of 33.0 months (range 0-209). Comparing pre-pandemic (2018-2019) to early pandemic years (2020-2021), the IPD rate in children < 18 years decreased by 60.6% (p < 0.001). However, no significant change was observed when comparing 2022 to 2018. The most common diagnoses were pneumonia (61.8%), meningitis (14.5%), and bacteremia without focus (13.2%). Serotype 3 was the leading cause (35.1%) of IPD and was associated with complicated pneumonia (84.7%) and vaccine failure (73.6%). Ninety-three IPD episodes (45.4%) were caused by PCV13 serotypes, 97 (47.3%) by PCV15 serotypes, and 132 (64.4%) by PCV20 serotypes. CONCLUSION: The incidence of IPD has remained stable, except for a decrease during the pandemic. Serotype 3 was the most common, often associated with vaccine failures and severe pneumonia. PCV15 and PCV20 vaccines could offer better coverage against circulating serotypes and further reduce IPD incidence in Catalonia. WHAT IS KNOWN: • Serotype 3 remains a leading cause of invasive pneumococcal disease (IPD) despite inclusion in PCV13 due to its limited vaccine effectiveness. • IPD incidence decreased globally during the COVID-19 pandemic, likely due to public health measures. WHAT IS NEW: • In Catalonia, serotype 3 continues to dominate pediatric IPD cases and is frequently associated with complicated pneumonia and vaccine failure. • PCV15 and PCV20 offer broader serotype coverage and may significantly improve IPD prevention in children.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=28559
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=28559
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER
publisher.none.fl_str_mv SPRINGER
dc.source.none.fl_str_mv EUROPEAN JOURNAL OF PEDIATRICS
ISSN: 03406199
ISSNe: 14321076
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422626796994560
score 15,81155

Registros relacionados